Pan glutamine blockade using 6-diazo-5-oxo-l-norleucine (DON), either alone or in combination with anti-PD-1 therapy, or even through GLS-specific inhibition during CD8 T-cell activation, has demonstrated enhancement in CD8 cytotoxicity and overall anti-tumor activity [210]. This evidence concerns the gene CD8A and neoplasm.